KURA ONCOLOGY INC (KURA) — insider trading
Health Care · NASDAQ
KURA ONCOLOGY INC (KURA) has 29 reported SEC Form 4 insider transactions in our data, including 2 open-market purchases and 17 open-market sales among the most recent 29 (latest 2026-09-29).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-29 | Leoni Mollie | Officer (Chief Medical Officer) | Open-market sale | 28,802 | $10.75 | $309.6K | Form 4 |
| 2026-09-29 | Powl Brian T. | Officer (Chief Commercial Officer) | Open-market sale | 15,430 | $10.75 | $165.9K | Form 4 |
| 2026-09-29 | FORD KATHLEEN | Officer (Chief Operating Officer) | Open-market sale | 3,668 | $10.75 | $39.4K | Form 4 |
| 2026-09-28 | Leoni Mollie | Officer (Chief Medical Officer) | Open-market sale | 12,448 | $10.50 | $130.7K | Form 4 |
| 2026-09-28 | Powl Brian T. | Officer (Chief Commercial Officer) | Open-market sale | 8,000 | $10.56 | $84.5K | Form 4 |
| 2026-09-28 | Powl Brian T. | Officer (Chief Commercial Officer) | Open-market sale | 9,020 | $10.50 | $94.7K | Form 4 |
| 2026-09-28 | FORD KATHLEEN | Officer (Chief Operating Officer) | Open-market sale | 6,906 | $10.50 | $72.5K | Form 4 |
| 2026-09-28 | DOYLE THOMAS JAMES | Officer (SVP, Finance & Accounting) | Open-market sale | 4,607 | $10.50 | $48.4K | Form 4 |
| 2026-09-28 | Bair Teresa Brophy | Officer (Chief Legal Officer) | Open-market sale | 8,442 | $10.50 | $88.6K | Form 4 |
| 2026-09-24 | Burrows Francis | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-09-24 | Burrows Francis | Officer (Chief Scientific Officer) | Open-market sale | 20,726 | $10.83 | $224.5K | Form 4 |
| 2026-09-24 | Burrows Francis | Officer (Chief Scientific Officer) | Option exercise / conversion | 30,000 | $6.15 | $184.5K | Form 4 |
| 2026-09-08 | Fulk Jennifer | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 450,000 | — | $0 | Form 4 |
| 2026-08-24 | WILSON TROY EDWARD | Director, Officer (President and CEO) | Open-market purchase | 100,000 | $12.39 | $1.24M | Form 4 |
| 2026-08-21 | Powl Brian T. | Officer (Chief Commercial Officer) | Open-market sale | 4,345 | $11.89 | $51.7K | Form 4 |
| 2026-08-19 | Bair Teresa Brophy | Officer (Chief Legal Officer) | Open-market sale | 31,487 | $12.63 | $397.7K | Form 4 |
| 2026-08-17 | WILSON TROY EDWARD | Director, Officer (President and CEO) | Open-market purchase | 100,000 | $11.12 | $1.11M | Form 4 |
| 2026-06-18 | Leoni Mollie | Officer (Chief Medical Officer) | Open-market sale | 84,929 | $9.82 | $834.3K | Form 4 |
| 2026-06-04 | Malley Thomas | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-04 | Szela Mary T | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-04 | SCHAFER CAROL | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-04 | Collins Helen Louise | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-04 | Hasnain Faheem | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-04 | VASCONCELLES MICHAEL | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-04 | Parks Diane L. | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-05-21 | Powl Brian T. | Officer (Chief Commercial Officer) | Open-market sale | 10,000 | $11.00 | $110.0K | Form 4 |
| 2026-05-19 | FORD KATHLEEN | Officer (Chief Operating Officer) | Open-market sale | 2,257 | $9.08 | $20.5K | Form 4 |
| 2026-05-19 | Powl Brian T. | Officer (Chief Commercial Officer) | Open-market sale | 339 | $9.21 | $3.1K | Form 4 |
| 2026-05-18 | Bair Teresa Brophy | Officer (Chief Legal Officer) | Open-market sale | 2,256 | $9.38 | $21.2K | Form 4 |
Ask the chat about KURA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: KURA ONCOLOGY INC (KURA).
Last updated 2026-09-29 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.